Full Archive
Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study
European Journal of Surgical Oncology 2026 January 17 [Link] Lukas Pollmann, Jürgen Zieren, Nicola S Pollmann, Urs Giger-Pabst, Pompiliu Piso, Michael Ströhlein, Nicola Cerasani, Fabian Kockelmann, Maximilian Schmeding Abstract Background: For carefully selected patients with peritoneal surface malignancies (PSMs), secondary cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide similar oncological results as…
Read MoreCancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma
Cancer Science 2026 January 20 [Link] Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to…
Read MoreRisk Factors of Hematological Toxicity of Mesothelioma Treatment-A Territory-Wide Retrospective Study
Thoracic Cancer 2026 January [Link] Wang Chun Kwok, Desmond Yat Hin Yap, Isaac Sze Him Leung, James Chung Man Ho Abstract Background: While chemotherapy remains the treatment of choice for mesothelioma, it carries significant toxicities, especially hematological toxicity. Methods: We conducted this territory-wide retrospective study in Hong Kong to investigate the prevalence and risk factors…
Read MoreMesothelioma Contrast Pharmacokinetics: A Feasibility Trial of the Use of Pharmacokinetic Analysis in Small-Volume Pleural Malignancy
Radiology. Cardiothoracic Imaging 2026 February [Link] Gordon W Cowell, Selina Tsim, David B Stobo, Colin Noble, Catherine A Humphreys, Rosie Woodward, John E Foster, Craig Dick, Kevin G Blyth Abstract Purpose To assess the feasibility of dynamic contrast-enhanced (DCE) MRI-derived pharmacokinetic factor acquisition and performance in patients with suspected small-volume pleural malignancy. Materials and Methods…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read MoreCytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm
Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreMulti-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations
Lung Cancer 2026 February [Link] Kathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, Elly Marcq, Adrian Covaci, Ken Op de Beeck, Jan P van Meerbeeck, Jo Raskin, Annelies Janssens, Annemiek Snoeckx, Kevin Lamote Abstract Objectives: Pleural mesothelioma (PM) is an aggressive thoracic cancer related to historical exposure to asbestos fibres. Symptoms often appear at an advanced stage,…
Read More
Skip to content